P.329 State anxiety induced by THC and CBD does not change after correcting for baseline anxiety levels
| Autor: | F. Vinckenbosch, J.G. Ramaekers, T. Arkell, Nadia R P W Hutten, Kim P. C. Kuypers, Eef L. Theunissen, Iain S. McGregor |
|---|---|
| Přispěvatelé: | Section Psychopharmacology, RS: FPN NPPP II |
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Future studies biology business.industry biology.organism_classification Placebo Anxiety state Psychiatry and Mental health Neurology mental disorders medicine Trait anxiety Anxiety Pharmacology (medical) Neurology (clinical) Cannabis medicine.symptom business Cannabidiol Biological Psychiatry medicine.drug Clinical psychology Stroop effect |
| Zdroj: | European Neuropsychopharmacology, 44, S60-S61. Elsevier |
| ISSN: | 0924-977X |
| DOI: | 10.1016/j.euroneuro.2021.01.090 |
| Popis: | Background: In the last decade, the psychoactive substance delta-9-tetrahydrocannabinol (THC) in cannabis products has risen considerably, which has been associated with increased anxiety [1]. The non-psychoactive cannabis compound cannabidiol (CBD) is suggested to counteract THC-induced anxiety to some extent [2,3], however, these effects are mild [3]. Trait anxiety has been suggested to moderate cannabis-induced anxiety [4]. The present study aimed to examine whether the CBD effects on THC-induced anxiety can be explained by baseline state anxiety levels and/or trait anxiety levels in healthy volunteers. Methods: A placebo-controlled, randomized within-subjects study including 26 healthy recreational cannabis users was set up to test the effects of vaporized cannabis containing THC (11% THC |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect